Please provide your email address to receive an email when new articles are posted on . Transcatheter mitral valve repair improved clinical outcomes in patients with HF across all quartiles of mitral ...

A new, retrospective study trying to tease out the benefits of MitraClip procedures according to the etiology of mitral regurgitation (MR) hints that, compared with conservative management, ...

CHICAGO, IL—An analysis of patients treated with the MitraClip since its US approval in 2013 suggests that certain subtypes of both degenerative and functional mitral regurgitation (MR) may be ...

CHICAGO -- Emerging real-world data supported benefits of MitraClip therapy in patients with secondary mitral regurgitation (MR) who didn't fit the COAPT profile, the EXPAND study showed. MR was often ...

SAN DIEGO — Patients with HF with moderate to severe or severe functional mitral regurgitation who underwent transcatheter mitral valve repair reduced the risk for HF hospitalization and mortality ...

January 6, 2012 (London, United Kingdom) — Results from the high-surgical-risk arm of the EVEREST II trial with the percutaneous MitraClip (Abbott) device, suggesting reduced mitral regurgitation and ...

Global health care major Abbott Laboratories ABT recently presented one-year positive outcomes from the study of the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the U.S.

Secondary mitral regurgitation (MR) can be a serious complication of heart failure — in a recent study, two-thirds of the people who were taking the maximum recommended doses of drugs for severe forms ...

A seemingly simple but sophisticated clip may usher in a “new era” for patients suffering from a severe and difficult-to-treat complication of heart failure, according to a new study. The device, ...

Abbott Laboratories ABT recently announced FDA approval for its latest version of MitraClip heart valve repair device to treat mitral regurgitation (MR). With the approval for the fourth-generation ...

Abbott Laboratories ABT recently announced favorable results from two distinctly-conducted analyses of the two-year long COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...